prikaz prve stranice dokumenta Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?
  Download
PDF 1.16 MB
Scientific paper - Review paper
Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?
World J Gastroenterol, 22 (2016), 32; 7236-7251. urn:nbn:hr:184:683246
Mikolašević, Ivana; Orlić, Lidija; Franjić, Neven; Hauser, Goran; Štimac, Davor; Milić, Sandra

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Mikolašević, I., Orlić, L., Franjić, N., Hauser, G., Štimac, D. & Milić, S. (2016). Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?. World J Gastroenterol, 22. (32), 7236-7251. Retrieved from https://urn.nsk.hr/urn:nbn:hr:184:683246

Mikolašević, Ivana, et al. "Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?." World J Gastroenterol, vol. 22, no. 32, 2016, pp. 7236-7251. https://urn.nsk.hr/urn:nbn:hr:184:683246

Mikolašević, Ivana, Lidija Orlić, Neven Franjić, Goran Hauser, Davor Štimac and Sandra Milić. "Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?." World J Gastroenterol 22, no. 32 (2016): 7236-7251. https://urn.nsk.hr/urn:nbn:hr:184:683246

Mikolašević, I., et al. (2016) 'Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?', World J Gastroenterol, 22(32), pp. 7236-7251. Available at: https://urn.nsk.hr/urn:nbn:hr:184:683246 (Accessed 23 November 2024)

Mikolašević I, Orlić L, Franjić N, Hauser G, Štimac D, Milić S. Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?. World J Gastroenterol [Internet]. 2016 August 28 [cited 2024 November 23];22(32):7236-7251. Available at: https://urn.nsk.hr/urn:nbn:hr:184:683246

I. Mikolašević, L. Orlić, N. Franjić, G. Hauser, D. Štimac and S. Milić, "Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?", World J Gastroenterol, vol. 22, no. 32, pp. 7236-7251, August 2016. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:683246. [Accessed: 23 November 2024]

Metadata
Title (english)Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?
AuthorIvana Mikolašević
AuthorLidija Orlić
AuthorNeven Franjić
AuthorGoran Hauser
AuthorDavor Štimac
AuthorSandra Milić
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. Currently, the routinely used modalities are unable to adequately determine the levels of steatosis and fibrosis (laboratory tests and ultrasonography) or cannot be applied as a screening procedure (liver biopsy). Among the non-invasive tests, transient elastography (FibroScan®, TE) with controlled attenuation parameter (CAP) has demonstrated good accuracy in quantifying the levels of liver steatosis and fibrosis in patients with NAFLD, the factors associated with the diagnosis and NAFLD progression. The method is fast, reliable and reproducible, with good intra- and interobserver levels of agreement, thus allowing for population-wide screening and disease follow-up. The initial inability of the procedure to accurately determine fibrosis and steatosis in obese patients has been addressed with the development of the obese-specific XL probe. TE with CAP is a viable alternative to ultrasonography, both as an initial assessment and during follow-up of patients with NAFLD. Its ability to exclude patients with advanced fibrosis may be used to identify low-risk NAFLD patients in whom liver biopsy is not needed, therefore reducing the risk of complications and the financial costs.
Keywords (english)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleWorld J Gastroenterol
Numberingvol. 22, no. 32, pp. 7236-7251
e-ISSN1007-9327
URN:NBNurn:nbn:hr:184:683246
Publication2016-08-28
Document URLhttps://www.wjgnet.com/1007-9327/full/v22/i32/7236.htm
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) icon
Created on2017-09-17 12:56:39